Ana Radeljevic
Director/Board Member at MERRIMACK PHARMACEUTICALS, INC.
Ana Radeljevic active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Director/Board Member | 05/06/2022 | - |
| Independent Dir/Board Member | 05/06/2022 | - | |
ADRx, Inc.
 ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 31/08/2021 | - |
Career history of Ana Radeljevic
Former positions of Ana Radeljevic
| Companies | Position | Start | End |
|---|---|---|---|
| REVVITY, INC. | Corporate Officer/Principal | 31/12/2013 | 31/12/2015 |
Training of Ana Radeljevic
| Syracuse University | Masters Business Admin |
| Old Dominion University | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| REVVITY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ADRx, Inc.
ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Health Technology |
- Stock Market
- Insiders
- Ana Radeljevic
- Experience